We would love to hear your thoughts about our site and services, please take our survey here.
Video of the Angle conference presentation which took place today (thanks for flagging the conference to goosed on AD).
hTTps://www.youtube.com/watch?v=ZqaWMUx7GhE
Quite the opposite Matt - based on what Lindy actually said I would expect at least one or two mAb deals this year (5 parties in discussion, vying for exclusivity).
'Oh and of course they initially went down the wrong DDA approval pathway, which set things back quite a bit.
Have to wonder why that was as there are plenty of consultants firms that help companies prepare submissions. '
LOL. It was a consulting firm that sent them down the wrong path.
The benefit of using NGS provided by the mayor players in this space is that there is a very large installed base of those machines across labs globally, so all Angle need to do is to publish the protocol for processing the CTC's through those systems and then those labs can carry out the CTC analysis themselves (assuming they buy a parsortix system) and can therefore provide the future Ovarian / Prostate tests and other tests themselves. If Angle stuck with their in-house genetic analysis solution for their tests then the labs would need to buy the Angle genetic testing tech as well as buying the parsortix systems and this would be a major blocker to other labs offering the tests.
Hi VanVan
we know that Genmab are interested in a further Glymab and that there is work ongoing with another company to determine if Scancell's tech works with theirs, and no doubt there are other discussion underway since the new Business Development Director came on board. The next deal can't be too far away.
Banshee's on the other site made the point about ctDNA analysis being much quicker than CTC DNA analysis due to the 2 hours taken to separate the CTC's and clean the machine. I don't see this as an obstacle. Consider the following:-
- If a lab has 5 parsortix machines used in parallel they could do 5 CTC DNA analyses every 3 hours.
- Lets say the lab charges $1500 for the CTC DNA separation and analysis, of which they attribute $500 for the CTC separation stage.
- So every 3 hours simply for the separation process they can make 5 x $500 (i.e.$2500) minus the cost of 5 cassettes ($500) and the cost of the lab technician ($150).
- So every 3 hours they can make $1850 profit.
- if the lab works 6 days a week for 9 hours per day this equates to the lab making just over $1.7m profit per year doing CTC separations from just 5 parsortix machines in one lab.
- Angle make $468k from the sale of the cassettes.
And this is from a single lab with just 5 machines. A lot of potential profit for the lab which would surely encourage labs to adopt the technology and offer the service.
It doesn't take much imagination to see how much revenue could flow from the adoption of CTC DNA analysis alongside ctDNA analysis.
I guess most of us have seen the stellar rise of Angle today (and I know a number of us hold shares). Wouldn't it have been great to buy Angle at 11p just a few trading days ago ! Well, don't be left in the same position regarding Scancell, regretting not buying at 11p.
'Yes. Anytime now I would imagine. However the directors refuse to be drawn on whether it will be Ovarian or Prostate first.'
I guess this means they are probably running neck and neck and therefore we should get one shortly after the other....
JustThinkItThrough
the standalone device can't be used make any diagnostic/prognostic claims for CTCs because its job is to get the CTC's from patient blood - analysis of those CTC's using other tools then has to take place for diagnosis / prognosis to be performed. Absolutely no reason why this can't happen.
Regarding research us, particularly in clinical trials, this could well grow into a significant business in its own right. Review previous Angle presentations to get a sense of the potential scale.